Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML): Analysis of Socioeconomic Factors Using National Cancer Data Base (NCDB)

Occurrence of Secondary Acute Myeloid Leukemia in a Patient with Breast Cancer after Chemotherapy

acute myeloid leukemia (aml): the role of intensive induction chemotherapy

intensive induction therapy-in acute myeloid leukemia (aml), as in some other systemic malignancies- is a strategy fundamentally different from post-remission strategies. approaches like consolidation treatment, prolonged mainte nance, and autologous or allogeneic transplantation in the first remission are directed against minimal residual disease with a malignant cell population having survive...

Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: A National Cancer Data Base (NCDB) analysis.

BACKGROUND For node-positive vulvar cancer, adjuvant radiotherapy has an established benefit, whereas the impact of chemotherapy is unknown. A National Cancer Data Base (NCDB) analysis was conducted to determine patterns of care and evaluate the survival impact of adjuvant chemotherapy. METHODS The NCDB was queried for vulvar cancer patients diagnosed from 1998-2011 who underwent extirpative ...

Survival in elderly acute myeloid leukemia patients.

We read with interest the paper by Pulsoni et al. on survival in unselected elderly patients. We would like to back their conclusions with a brief presentation of our data. Between 1992 and 2003, 159 non-M3 AML patients over 60 years were diagnosed and treated in our institution. 34 patients (21.9%) were treated with aggressive induction chemotherapy (daunorubicin/idarubicin + cytarabine ± etop...

Oral induction and consolidation chemotherapy with idarubicin and etoposide in elderly patients with acute myeloid leukemia.

Haematologica/journal of hematology vol. 88(02):February 2003 229 ics of STI571 in a phase 1 trial in chronic myelogenous leukemia (CML) patients. Proc Am Assoc Cancer Res 2000;41:3468[abstract]. 4. Druker BJ, Lydon NB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3-7. 5. Marin D, Marktel S, Bua M, Olavarria E,...